These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
307 related items for PubMed ID: 32955460
21. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. Zhang H, Therriault J, Kang MS, Ng KP, Pascoal TA, Rosa-Neto P, Gauthier S, Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Res Ther; 2018 Aug 16; 10(1):80. PubMed ID: 30115118 [Abstract] [Full Text] [Related]
22. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature. Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R. J Alzheimers Dis; 2013 Aug 16; 36(2):401-8. PubMed ID: 23609762 [Abstract] [Full Text] [Related]
23. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF. Bipolar Disord; 2016 Feb 16; 18(1):63-70. PubMed ID: 26876913 [Abstract] [Full Text] [Related]
24. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Baldeiras I, Santana I, Leitão MJ, Vieira D, Duro D, Mroczko B, Kornhuber J, Lewczuk P. Alzheimers Res Ther; 2019 Jan 05; 11(1):2. PubMed ID: 30611311 [Abstract] [Full Text] [Related]
25. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Palmqvist S, Zetterberg H, Mattsson N, Johansson P, Alzheimer's Disease Neuroimaging Initiative, Minthon L, Blennow K, Olsson M, Hansson O, Swedish BioFINDER Study Group. Neurology; 2015 Oct 06; 85(14):1240-9. PubMed ID: 26354982 [Abstract] [Full Text] [Related]
26. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. J Alzheimers Dis; 2015 Oct 06; 45(4):1077-88. PubMed ID: 25649653 [Abstract] [Full Text] [Related]
27. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C, Alzheimer's Neuroimaging Initiative. Neuroimage Clin; 2014 Oct 06; 4():164-73. PubMed ID: 24371799 [Abstract] [Full Text] [Related]
28. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. Wang H, Stewart T, Toledo JB, Ginghina C, Tang L, Atik A, Aro P, Shaw LM, Trojanowski JQ, Galasko DR, Edland S, Jensen PH, Shi M, Zhang J, Alzheimer’s Disease Neuroimaging Initiative. J Alzheimers Dis; 2018 Oct 06; 61(4):1541-1553. PubMed ID: 29376878 [Abstract] [Full Text] [Related]
30. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M. Dement Geriatr Cogn Disord; 2009 Oct 06; 27(5):458-64. PubMed ID: 19420940 [Abstract] [Full Text] [Related]
31. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Christl J, Verhülsdonk S, Pessanha F, Menge T, Seitz RJ, Kujovic M, Höft B, Supprian T, Lange-Asschenfeldt C. J Alzheimers Dis; 2019 Oct 06; 72(4):1119-1127. PubMed ID: 31683478 [Abstract] [Full Text] [Related]
32. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease. Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando SB, Lauridsen C, Berge G, Grøntvedt GR, Bråthen G, White LR, Kultima K, Nielsen HM. Alzheimers Res Ther; 2022 Aug 24; 14(1):115. PubMed ID: 36002891 [Abstract] [Full Text] [Related]
33. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment. He B, Wang L, Xu B, Zhang Y, Alzheimer’s Disease Neuroimaging Initiative. Neurosci Lett; 2021 May 29; 754():135765. PubMed ID: 33667602 [Abstract] [Full Text] [Related]
34. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network. Benson GS, Bauer C, Hausner L, Couturier S, Lewczuk P, Peters O, Hüll M, Jahn H, Jessen F, Pantel J, Teipel SJ, Wagner M, Schuchhardt J, Wiltfang J, Kornhuber J, Frölich L. J Neural Transm (Vienna); 2022 Jun 29; 129(5-6):477-486. PubMed ID: 35061102 [Abstract] [Full Text] [Related]
35. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease. García-Escobar G, Puig-Pijoan A, Puente-Periz V, Fernández-Lebrero A, María Manero R, Navalpotro-Gómez I, Suárez-Calvet M, Grau-Rivera O, Contador-Muñana J, Cascales-Lahoz D, Duran-Jordà X, Boltes N, Pont-Sunyer MC, Ortiz-Gil J, Carrillo-Molina S, López-Villegas MD, Abellán-Vidal MT, Martínez-Casamitjana MI, Hernández-Sánchez JJ, Padrós-Fluvià A, Peña-Casanova J, Sánchez-Benavides G. J Alzheimers Dis; 2023 Jun 29; 92(4):1303-1321. PubMed ID: 37038810 [Abstract] [Full Text] [Related]
36. Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer's continuum. Jiang J, Zhuo Z, Wang A, Li W, Jiang S, Duan Y, Ren Q, Zhao M, Wang L, Yang S, Awan MUN, Liu Y, Xu J. Alzheimers Res Ther; 2024 Jul 03; 16(1):149. PubMed ID: 38961406 [Abstract] [Full Text] [Related]
37. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease. Teuber-Hanselmann S, Rekowski J, Vogelgsang J, von Arnim C, Reetz K, Stang A, Jöckel KH, Wiltfang J, Esselmann H, Otto M, Tumani H, Herring A, Keyvani K. J Neurol Neurosurg Psychiatry; 2020 Jan 03; 91(1):40-48. PubMed ID: 31371645 [Abstract] [Full Text] [Related]
38. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. Arch Neurol; 1998 Jul 03; 55(7):937-45. PubMed ID: 9678311 [Abstract] [Full Text] [Related]
39. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum. Paciotti S, Wojdała AL, Bellomo G, Toja A, Chipi E, Piersma SR, Pham TV, Gaetani L, Jimenez CR, Parnetti L, Chiasserini D. Alzheimers Res Ther; 2023 Jul 15; 15(1):124. PubMed ID: 37454217 [Abstract] [Full Text] [Related]
40. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K. JAMA; 2009 Jul 22; 302(4):385-93. PubMed ID: 19622817 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]